Dabrafenib is a BRAF inhibitor and has a good anti-tumor effect in BRAFV600E mutated cancer (131), whereas MEK inhibitor trametinib can enhance the inhibitory effect of BRAF (134). Here, BRAF is linked to neoplasm.